Aily Labs, an AI decision intelligence platform, announced an $80 million Series B funding round led by FPV Ventures, with participation from existing investor Insight Partners, J.P. Morgan, and other strategic investors.
The round represents one of 2025’s largest Series B closings for a female-founded AI startup and validates a critical insight that enterprises are no longer satisfied with AI tools that merely inform. They demand AI that acts.
Founded in 2020 by Bianca Anghelina, a former Novartis digital finance executive, Aily Labs addresses a problem that plagues Fortune 500 companies, organizational data remains siloed, fragmented, and inaccessible when decisions matter most.
Finance teams possess budget data. The supply chain operates independently. R&D functions in isolation. The result? Decisions that take weeks or months to reach, based on incomplete information and outdated processes.
Aily’s AI-native Decision Intelligence platform transforms this dynamic by integrating fragmented enterprise data into a single source of truth, then orchestrating what the company calls its “Super Agent,” an autonomous AI system that doesn’t just recommend decisions but executes them autonomously within defined parameters.
Most enterprise AI tools stop at recommendations. They generate dashboards, produce insights, and hand decision-making back to humans. Aily Labs transcends this limitation. The platform moves enterprises from raw data to measurable business impact in less than two weeks across finance, supply chain, R&D, and commercial operations.
Clients like Sanofi have experienced dramatic efficiency gains: what previously required weeks of manual forecasting and budget planning now occurs automatically.
“Companies can no longer afford to wait for insights, they need AI that acts,” said Bianca Anghelina, Founder and CEO of Aily Labs. “This funding lets us scale our Super Agent and Decision Intelligence LLM, enabling enterprises to make faster, smarter, and fully autonomous decisions that transform performance across every function, globally.”
This distinction matters because it addresses a widespread frustration among corporate executives. A significant percentage of CEOs report investing millions in AI infrastructure yet struggling to extract measurable ROI. Aily’s differentiation lies in its focus on decision-driven outcomes rather than insight generation alone.
Pegah Ebrahimi, Co-founder & Managing Partner at FPV Ventures, articulated what convinced the firm to lead the round: “I often hear from CEOs that they’re spending millions on AI, but can’t effectively deploy it or extract real business value from it. That’s what compelled us to invest in Aily Labs. CEOs tell us they’re making different decisions because of Aily’s AI, decisions that save money, grow revenue, and transform how their companies operate.”
The Path to $80 Million
Anghelina’s journey to this funding milestone began at Novartis, where she experienced firsthand the organizational paralysis created by siloed data. She observed talented decision-makers hamstrung by processes requiring weeks to consolidate information across departments. This friction inspired her to bootstrap Aily Labs in 2020 during the pandemic, building the first product with co-founder Sara Bisbe López in just eight weeks.
The company remained bootstrapped through Series A, prioritizing unit economics and organic growth through its pharma network. Insight Partners‘ entry in the Series A round brought strategic mentorship alongside capital, helping Anghelina build global sales infrastructure and expand her engineering organization.
Importantly, Aily Labs proved that execution at scale doesn’t require venture-stage funding from inception. The company achieved profitability and significant customer traction before raising external capital, then used that leverage to attract top-tier Series B investors who recognized proven product-market fit.
The $80 million will support four key initiatives. First, global expansion of Aily’s mobile-first Decision Intelligence App across new industries and geographies beyond healthcare. Second, advancement of autonomous AI agents that both recommend and execute high-impact decisions without human intervention.
Third, enhancement of Aily’s proprietary Decision Intelligence LLM with deeper enterprise expertise. Fourth, strengthening the company’s capital structure to sustain innovation and operational resilience.
This deployment reflects confidence in a market where enterprise leaders increasingly view AI adoption not as a discretionary nice-to-have but as a competitive necessity. Yet many executives remain frustrated by the gap between theoretical AI potential and actual business returns. Aily positions itself to close that gap through practical, ROI-focused implementation.
Anghelina envisions reaching one million users within Fortune 500 companies by 2027. She explicitly frames Aily’s mission as democratizing AI, making sophisticated autonomous decision-making accessible to any employee, regardless of technical expertise.
Amy Chang, board member at Aily Labs and experienced board member at multiple Fortune 50 companies, offered perspective on why this matters: “Aily bridges the gap between fragmented data and real-time decision-making through agentic AI. For leaders, that means what once took weeks now happens in minutes, enabling sharper execution and measurable growth.”
This vision extends beyond efficiency gains. It represents a fundamental reimagining of how large organizations make decisions. If Aily can prove that autonomous AI agents can reliably execute enterprise decisions across functions, reducing inefficiencies that currently cost corporations over $200 million annually, the market opportunity becomes massive.
